AC
ORIC icon

Aristides Capital’s Oric Pharmaceuticals ORIC Stock Holding History

Aristides Capital’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-70,000
Closed -$374K – 192
2022
Q1 		$374K Buy
+70,000
New +$630K 0.23% 101

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Aristides Capital's ORIC Position: Q2 2022 in Review

Aristides Capital sold out of Oric Pharmaceuticals (ORIC) in Q2 2022, closing a stake of 70,000 shares — an estimated $374K sold.

Aristides Capital first reported a position in ORIC in Q1 2022 and held it in 1 quarter. The position peaked at $374K in Q1 2022. 83 funds tracked by Wall St. Rank hold ORIC as of Q2 2022.

  • Aristides Capital reported no remaining Oric Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Aristides Capital sold 70,000 Oric Pharmaceuticals shares in Q2 2022, an estimated $374K.
  • Aristides Capital first reported a position in Oric Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Aristides Capital's Oric Pharmaceuticals position peaked at $374K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2022.

Based on Aristides Capital's 13F filing for Q2 2022, filed 15 Aug 2022.